Company news
Soleno Therapeutics, Inc. news in 2026
Soleno Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
May 7, 2026
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 5, 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
April 6, 2026
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
February 25, 2026
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
February 25, 2026
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4: 30 PM ET
February 11, 2026
Soleno Therapeutics to Participate in Upcoming Conferences
January 28, 2026
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
January 11, 2026
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
January 4, 2026